Targets

HER2

5 articles

Medicinal ChemistrybioRxiv

Trastuzumab-linked molecular glue steers cyclin K degradation toward HER2-positive breast cancer cells

  • The cyclin K glue degrader SAS1001 uses a solvent-exposed piperazine as its linker handle, tackling the lack of an obvious attachment site on glue scaffolds.
  • It degraded cyclin K via the ubiquitin-proteasome system and slowed growth across breast cancer cell lines.
  • Conjugated to trastuzumab, it entered HER2-positive cells preferentially, beating HER2-negative cells and a non-targeting conjugate; proteomics confirmed cyclin K loss.
PointsBased on the abstract

A solvent-exposed piperazine is a sensible exit vector, but glues are fickle: small changes near the DDB1-facing surface can abolish the ternary complex. Degradation needs showing for the linker-bearing payload, with cleavable against non-cleavable linkers, plus a CDK12 kinase-inhibitor control to separate degradation from plain CDK12 inhibition. And does the released glue reach enough intracellular exposure?

Industry NewsBioNTech / DualityBioEndpoints News

BioNTech and DualityBio's HER2 ADC wins a 'modest' Phase 3 in HR+/HER2-low breast cancer

  • The global Phase 3 DYNASTY-Breast02 trial of trastuzumab pamirtecan met its primary progression-free survival endpoint against physician's-choice chemotherapy.
  • Patients had chemotherapy-naive, HR+/HER2-low metastatic breast cancer that progressed on endocrine therapy.
  • The companies themselves call the benefit statistically significant but modest; overall survival data are still immature, and they are weighing next steps.
PointsBased on public reports

When the sponsors call their own win 'modest' in HER2-low, where Enhertu is the benchmark, they are signalling that this ADC will not displace it on efficacy. The more realistic path is a narrower niche or combinations, and the choice of next step will show how much BioNTech still wants to carry a HER2 ADC next to its bispecific bets.

Medicinal ChemistryACS Chemical Biology (ACS)

Coiled-coil masks keep T cell engagers silent until tumor proteases cut them loose

  • Anti-CD3 Fabs (OKT3, UCHT1) are sterically masked by leucine-zipper coiled-coil domains fused through protease-cleavable linkers, and paired with PSMA- or HER2-targeting nanobodies.
  • Masking strongly lowered CD3 binding, and protease cleavage restored most of it, both on recombinant CD3 and on T cell-displayed CD3.
  • Masked constructs did not activate Jurkat cells, whereas unmasked ones did.
  • MMP2-cleavable versions drove MMP2-dependent killing of PSMA+ and HER2+ cancer cells in PBMC co-cultures, aiming to limit on-target off-tumor toxicity.
PointsBased on the abstract

The appeal is that the mask is modular: swap the cleavable linker and the same leucine-zipper scaffold could, in principle, be retuned to a different protease, which is more flexible than hard-wiring one design. What I would press on is the gap between cleaved and unmasked binding, since 'most' restored is not full, and MMP2 is not strictly tumor-restricted. Only Jurkat and PBMC co-cultures here, so the off-tumor safety claim is still an aim, not data.

Industry NewsAstraZeneca / Daiichi SankyoSTAT News

NHS England to Reimburse AstraZeneca's Enhertu for HER2-Low Breast Cancer After US-UK Pricing Deal

  • Enhertu (trastuzumab deruxtecan), an AstraZeneca/Daiichi Sankyo HER2-targeting antibody-drug conjugate, will now be reimbursed by NHS England for HER2-low metastatic breast cancer.
  • The move reverses NICE's July 2024 rejection of the drug for this indication, ending a years-long access dispute.
  • It follows a new NICE agreement made possible by a broader U.S.-U.K. drug pricing deal (announced December 2025), which raised NICE's cost-effectiveness thresholds from about £20,000-£30,000 to £25,000-£35,000 per quality-adjusted life year.
  • A new quality-of-life assessment methodology, published August 27, 2026, also supported the reassessment.
  • About 1,000 women a year in England with HER2-low metastatic breast cancer are expected to now qualify, with studies reporting an average survival gain of roughly six months.
PointsBased on public reports

The science and data here are unchanged from NICE's 2024 rejection — this is a payer-economics win, not a clinical one, and it's easy to conflate the two. What actually moved was NICE's cost-effectiveness ceiling, from roughly £20-30K to £25-35K per QALY, engineered by the broader US-UK pricing deal, not new trial results. That's the real story: the first tangible commercial outcome traceable to that trade agreement, and it hands every company with a NICE-rejected asset a concrete playbook for reopening the case. Commercially, ~1,000 patients/year in England is a rounding error for AZ/Daiichi's global Enhertu franchise — the payoff is precedent, not revenue. Watch for ripple effects: rival ADCs and other HER2-low contenders now face a materially easier cost-effectiveness bar, reshaping competitive dynamics in an increasingly crowded ADC pipeline.

Industry NewsBayerFiercePharma

Bayer's Hyrnuo Wins FDA First-Line Approval for HER2-Mutated Lung Cancer, Sharpening Rivalry With Hernexeos

  • Hyrnuo (sevabertinib) is Bayer's oral, HER2-selective tyrosine kinase inhibitor (TKI).
  • The FDA granted accelerated approval expanding Hyrnuo to first-line use in adults with HER2 (ERBB2)-mutated, locally advanced or metastatic non-squamous NSCLC.
  • The nod is based on Phase I/II SOHO-01 data showing a 75% objective response rate in treatment-naive patients, with responses lasting over six months in 73% of cases.
  • It builds on Hyrnuo's November 2025 accelerated approval for previously treated patients with the same HER2-mutated tumor type.
  • Continued approval depends on the ongoing Phase III SOHO-02 trial versus standard of care in treatment-naive patients.
  • The move deepens Hyrnuo's rivalry with Boehringer Ingelheim's Hernexeos, which won its own first-line nod in February 2026, as the two oral TKIs vie for the small HER2-mutated NSCLC market.
PointsBased on public reports

Bayer is catching up, not leading. Boehringer's Hernexeos already claimed first-line HER2-mutated NSCLC in February 2026 — Hyrnuo's approval today closes that gap rather than opening a new front. Worth noting: this is accelerated approval built on single-arm Phase I/II SOHO-01 data (75% ORR, treatment-naive), with confirmatory Phase III SOHO-02 still reading out. Continued approval — and Bayer's ability to actually compete for first-line share — hinges on that trial beating standard of care head-to-head, not just replicating early response rates. Commercially, first-line access matters more than second-line ever will in a niche indication like this, since most patients get one shot at frontline therapy. If SOHO-02 disappoints, Bayer loses the label it just won; if it reads out clean, expect a genuine two-TKI market with prescribers picking on tolerability and durability data rather than brand.